ALIVUSPharmaceuticals
Alivus Life Sciences Limited — Cash Flow Statement
₹972.70
-0.40%
Alivus Life Sciences Limited Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | 225.34 Cr | 284.55 Cr | 143.21 Cr | 465.41 Cr | — |
| Issuance Of Capital Stock | 0.67 Cr | 0.00 | 0.00 | 1.01K Cr | — |
| Capital Expenditure | -166.19 Cr | -128.97 Cr | -162.80 Cr | -132.17 Cr | — |
| End Cash Position | 71.06 Cr | 301.41 Cr | 283.82 Cr | 512.16 Cr | — |
| Beginning Cash Position | 301.41 Cr | 283.82 Cr | 512.16 Cr | 115.60 Cr | — |
| Changes In Cash | -230.35 Cr | 17.59 Cr | -228.33 Cr | 396.56 Cr | — |
| Financing Cash Flow | -6.23 Cr | -279.44 Cr | -387.59 Cr | -78.80 Cr | — |
| Interest Paid Cff | -2.41 Cr | -1.55 Cr | -0.52 Cr | -27.76 Cr | — |
| Common Stock Dividend Paid | 0.00 | -275.69 Cr | -385.92 Cr | -128.65 Cr | — |
| Net Common Stock Issuance | 0.67 Cr | 0.00 | 0.00 | 1.01K Cr | — |
| Common Stock Issuance | 0.67 Cr | 0.00 | 0.00 | 1.01K Cr | — |
| Investing Cash Flow | -615.64 Cr | -116.48 Cr | -146.75 Cr | -122.23 Cr | — |
| Interest Received Cfi | 20.01 Cr | 12.02 Cr | 15.77 Cr | 6.67 Cr | — |
| Net Investment Purchase And Sale | -470.10 Cr | 0.00 | 0.11 Cr | 2.81 Cr | — |
| Purchase Of Investment | -470.10 Cr | 0.00 | — | — | -2.81 Cr |
| Net PPE Purchase And Sale | -165.56 Cr | -128.50 Cr | -162.62 Cr | -131.70 Cr | — |
| Sale Of PPE | 0.63 Cr | 0.47 Cr | 0.17 Cr | 0.47 Cr | — |
| Purchase Of PPE | -166.19 Cr | -128.97 Cr | -162.80 Cr | -132.17 Cr | — |
| Operating Cash Flow | 391.52 Cr | 413.51 Cr | 306.01 Cr | 597.59 Cr | — |
| Taxes Refund Paid | -162.95 Cr | -162.96 Cr | -153.56 Cr | -138.17 Cr | — |
| Change In Working Capital | -180.38 Cr | -134.08 Cr | -213.66 Cr | 99.84 Cr | — |
| Change In Other Current Assets | 44.52 Cr | -55.19 Cr | -73.56 Cr | 88.13 Cr | — |
| Change In Payable | 18.75 Cr | -34.12 Cr | 90.78 Cr | 73.75 Cr | — |
| Change In Inventory | -38.85 Cr | -82.63 Cr | -97.23 Cr | -2.82 Cr | — |
| Change In Receivables | -204.79 Cr | 37.86 Cr | -207.21 Cr | 28.91 Cr | — |
| Other Non Cash Items | -17.60 Cr | -10.47 Cr | -15.22 Cr | 21.18 Cr | — |
| Stock Based Compensation | 0.00 | 4.38 Cr | 3.19 Cr | 3.50 Cr | — |
| Provisionand Write Offof Assets | 31.98 Cr | 20.51 Cr | 9.30 Cr | — | — |
| Depreciation And Amortization | 60.61 Cr | 53.45 Cr | 42.09 Cr | 37.88 Cr | — |
| Depreciation | 60.61 Cr | 53.45 Cr | 40.65 Cr | 37.88 Cr | — |
| Pension And Employee Benefit Expense | 9.38 Cr | 7.80 Cr | 3.44 Cr | 3.18 Cr | — |
| Gain Loss On Investment Securities | -7.62 Cr | — | — | — | — |
| Net Foreign Currency Exchange Gain Loss | 2.15 Cr | -0.27 Cr | 0.89 Cr | -0.31 Cr | — |
| Gain Loss On Sale Of PPE | 1.82 Cr | 0.70 Cr | 0.56 Cr | 0.74 Cr | — |
| Net Income From Continuing Operations | 654.13 Cr | 631.29 Cr | 628.61 Cr | 564.92 Cr | — |
| Net Other Financing Charges | — | -0.02 Cr | -0.03 Cr | -932.87 Cr | -213.78 Cr |
| Cash Dividends Paid | — | -275.69 Cr | -385.92 Cr | -128.65 Cr | — |
| Sale Of Investment | — | 0.00 | 0.11 Cr | 2.81 Cr | — |
| Amortization Cash Flow | — | 3.67 Cr | 1.45 Cr | — | — |
| Net Issuance Payments Of Debt | — | — | 0.00 | -932.87 Cr | -213.78 Cr |
| Net Long Term Debt Issuance | — | — | 0.00 | -932.87 Cr | -213.78 Cr |
| Net Short Term Debt Issuance | — | — | — | — | -213.78 Cr |
| Net Other Investing Changes | — | — | — | — | -2.81 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Alivus Life Sciences Limited
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.